HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ASP8062

has shown therapeutic analgesic effects

Also Known As:

4-((6-(4,4-dimethylcyclohexyl)-2-methylthieno(2,3-d)pyrimidin-4-yl)methyl)-1lambda6-thiomorpholine-1,1-dione

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - ASP8062: 6
  - Oxazines: 9
    - Morpholines: 6
      - ASP8062: 6

Experts

1.	Marek, Gerard J: 2 articles (01/2022 - 03/2021)
2.	Blauwet, Mary Beth: 1 article (01/2022)
3.	Goldwater, Ronald: 1 article (01/2022)
4.	Heo, Nakyo: 1 article (01/2022)
5.	Ito, Mototsugu: 1 article (01/2022)
6.	Maruff, Paul: 1 article (01/2022)
7.	Spence, Anna: 1 article (01/2022)
8.	Ahmad, Maha: 1 article (03/2021)
9.	Freeman, Jon: 1 article (03/2021)
10.	Walzer, Mark: 1 article (03/2021)

Related Diseases

1.	Opioid-Related Disorders (Opiate Addiction) 04/01/2023 - "This study assessed the potential of ASP8062 for treating opioid use disorder (OUD). " 01/01/2022 - "ASP8062 is a novel orally active GABAB receptor positive allosteric modulator in clinical development for the treatment of alcohol use disorder (AUD) and opioid use disorder (OUD). " 01/01/2023 - "A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder."
2.	Substance-Related Disorders (Drug Abuse) 01/01/2023 - "ASP8062 did not enhance substance use-related TEAEs, respiratory depression, or suicidal ideation and did not have a clinically significant impact on the PK of B/N. " 01/01/2023 - "These data suggest a potentially low risk for an increase in drug abuse- or withdrawal-related adverse events or respiratory distress in participants exposed to ASP8062 and morphine." 01/01/2023 - "ASP8062 plus morphine did not increase respiratory depression, potential drug abuse- or withdrawal-related adverse events. "
3.	Respiratory Insufficiency (Respiratory Failure) 01/01/2023 - "ASP8062 did not enhance substance use-related TEAEs, respiratory depression, or suicidal ideation and did not have a clinically significant impact on the PK of B/N. " 01/01/2023 - "ASP8062 plus morphine did not increase respiratory depression, potential drug abuse- or withdrawal-related adverse events. "
4.	Myalgia 12/15/2019 - "Oral administration of ASP8062 significantly reversed the decrease in muscle pressure threshold in reserpine-induced myalgia rats. "
5.	Pain (Aches) 12/15/2019 - "We examined the in vitro profiles of ASP8062, the effects of a GABAB receptor PAM and an agonist on pain in a rat model of FM, and the sleep/wake cycle, EEG during sleep stages and motor coordination in rats. "

Related Drugs and Biologics

1.	Naloxone Drug Combination Buprenorphine
2.	Reserpine (Serpasil)
3.	Morphine (MS Contin)
4.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Oral Administration